TOPICAL IMMUNOMODULATOR CRITERIA Pharmacology: Pimecrolimus inhibits the calcium-dependent phosphatase (calcineurin), interfering with T-cell activation and transcription of early cytokines. Thus, it decreases the synthe - Pimecrolimus - Document - PDFSEARCH.IO

First Page	Meta Content
	TOPICAL IMMUNOMODULATOR CRITERIA Pharmacology: Pimecrolimus inhibits the calcium-dependent phosphatase (calcineurin), interfering with T-cell activation and transcription of early cytokines. Thus, it decreases the synthe Add to Reading List Document Date: 2014-09-11 16:48:58 Open Document File Size: 24,79 KB Share Result on Facebook Company Novartis / / IndustryTerm Treatment of Netherton’s Syndrome / Treatment of psoriasis / / MedicalCondition psoriasis C. Treatment / severe atopic dermatitis / inflammatory cytokines / atopic dermatitis / infected atopic dermatitis D. Treatment / / Organization Dermatology Association / American Academy of Dermatology / Pharmacy & Therapeutic Committee Commissioner DUR Board / / Position Commissioner / / Product diflorasone diacetate / hydrocortisone acetate / ELIDEL / PROTOPIC / / SocialTag Corticosteroids Chemistry Tacrolimus Pimecrolimus Health Autoimmune diseases Medicine Atopic dermatitis Atopy Immunosuppressants

TOPICAL IMMUNOMODULATOR CRITERIA Pharmacology: Pimecrolimus inhibits the calcium-dependent phosphatase (calcineurin), interfering with T-cell activation and transcription of early cytokines. Thus, it decreases the syntheAdd to Reading List